In a Q&A, Joann Ferguson, the health system's VP of revenue cycle, explains how the technology saves time and money and improves revenue cycle and clinical processes.
JAK inhibitors were not associated with higher risk of myocardial infarction or stroke and venous thromboembolism, compared with TNF-inhibitor users, in a small study.